Surgical Delay Is Associated with Improved Survival in Hepatocellular Carcinoma: Results of the National Cancer Database.
Cancer survival
Hepatocellular carcinoma
National Cancer Database
Surgical delay
Wait time
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
04
05
2018
accepted:
07
08
2018
pubmed:
18
10
2018
medline:
9
7
2020
entrez:
18
10
2018
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is one of the fastest growing causes of cancer-related death in the USA. Studies that investigated the impact of HCC therapeutic delays are limited to single centers, and no large-scale database research has been conducted. This study investigated the association of surgical delay and survival in HCC patients. Patients underwent local tumor destruction and hepatic resection for stages I-III HCC were identified from the 2004 to 2013 Commission on Cancer's National Cancer Database. Surgical delay was defined as > 60 days from the date of diagnosis to surgery. Generalized linear-mixed model assessed the demographic and clinical factors associated with delay, and frailty Cox proportional hazard analysis examined the prognostic factors for overall survival. A total of 12,102 HCC patients met the eligibility criteria. Median wait time to surgery was 50 days (interquartile range, 29-86), and 4987 patients (41.2%) had surgical delay. Delayed patients demonstrated better 5-year survival for local tumor destruction (29.1 vs. 27.6%; P = .001) and resection (44.1 vs. 41.0%; P = .007). Risk-adjusted model indicated that delayed patients had a 7% decreased risk of death (HR, 0.93; 95% CI, 0.87-0.99; P = .027). Similar findings were also observed using other wait time cutoffs at 50, 70, 80, 90, and 100 days. A plausible explanation of this finding may be case prioritization, in which patients with more severe and advanced disease who were at higher risk of death received earlier surgery, while patients with less-aggressive tumors were operated on later and received more comprehensive preoperative evaluation.
Sections du résumé
BACKGROUND
Hepatocellular carcinoma (HCC) is one of the fastest growing causes of cancer-related death in the USA. Studies that investigated the impact of HCC therapeutic delays are limited to single centers, and no large-scale database research has been conducted. This study investigated the association of surgical delay and survival in HCC patients.
METHODS
Patients underwent local tumor destruction and hepatic resection for stages I-III HCC were identified from the 2004 to 2013 Commission on Cancer's National Cancer Database. Surgical delay was defined as > 60 days from the date of diagnosis to surgery. Generalized linear-mixed model assessed the demographic and clinical factors associated with delay, and frailty Cox proportional hazard analysis examined the prognostic factors for overall survival.
RESULTS
A total of 12,102 HCC patients met the eligibility criteria. Median wait time to surgery was 50 days (interquartile range, 29-86), and 4987 patients (41.2%) had surgical delay. Delayed patients demonstrated better 5-year survival for local tumor destruction (29.1 vs. 27.6%; P = .001) and resection (44.1 vs. 41.0%; P = .007). Risk-adjusted model indicated that delayed patients had a 7% decreased risk of death (HR, 0.93; 95% CI, 0.87-0.99; P = .027). Similar findings were also observed using other wait time cutoffs at 50, 70, 80, 90, and 100 days.
CONCLUSIONS
A plausible explanation of this finding may be case prioritization, in which patients with more severe and advanced disease who were at higher risk of death received earlier surgery, while patients with less-aggressive tumors were operated on later and received more comprehensive preoperative evaluation.
Identifiants
pubmed: 30328070
doi: 10.1007/s11605-018-3925-4
pii: 10.1007/s11605-018-3925-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
933-943Références
Scand J Gastroenterol. 2007 Apr;42(4):485-92
pubmed: 17454859
BJU Int. 2002 Jun;89(9):868-78
pubmed: 12010230
Thorax. 2004 Jan;59(1):45-9
pubmed: 14694247
Br J Cancer. 2015 Mar 31;112 Suppl 1:S92-107
pubmed: 25734382
Clin Genitourin Cancer. 2017 Dec;15(6):689-695.e2
pubmed: 28558988
BMJ. 2002 Jul 27;325(7357):196
pubmed: 12142308
CA Cancer J Clin. 2017 Jul 8;67(4):273-289
pubmed: 28586094
HPB (Oxford). 2015 Sep;17(9):747-52
pubmed: 26278321
Ann Hepatol. 2017 Aug 8;16(5):765-771
pubmed: 28809734
JAMA Oncol. 2017 Dec 1;3(12):1722-1728
pubmed: 28241198
J Hepatol. 2017 Oct 6;:
pubmed: 28989094
J Surg Oncol. 2011 Feb;103(2):133-9
pubmed: 21259246
Ann Surg. 2011 Apr;253(4):779-85
pubmed: 21475020
Hepatology. 2015 Jan;61(1):184-90
pubmed: 25234419
Clin Gastroenterol Hepatol. 2013 May;11(5):472-7
pubmed: 23200983
J Transplant. 2016;2016:7926264
pubmed: 27413539
HPB (Oxford). 2010 Nov;12(9):644-8
pubmed: 20961373
Clin Transl Oncol. 2010 Dec;12(12):836-42
pubmed: 21156415
J Thorac Oncol. 2011 Jul;6(7):1254-9
pubmed: 21610526
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Ann Surg Oncol. 2014 Nov;21(12):3909-16
pubmed: 24849522
J Hepatol. 2011 May;54(5):1055-62
pubmed: 21145846
J Am Coll Surg. 2017 Aug;225(2):216-225
pubmed: 28414114
J Natl Compr Canc Netw. 2013 Sep 1;11(9):1101-8
pubmed: 24029125